Loading...
•
Dec 31, 2021
COMPASS Q4 2021 Earnings Report
Reported financial results for Q4 and full year 2021 and provided a business update.
Key Takeaways
COMPASS Pathways reported a net loss for the quarter ended December 31, 2021, was $25.7 million, or $0.61 loss per share. The company's cash and cash equivalents were $273.2 million as of December 31, 2021.
Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support
Positive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRD
Launch of phase II study of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD)
New senior executives appointed: Dr Guy Goodwin as Chief Medical Officer, Mike Falvey as Chief Financial Officer and Matt Owens as General Counsel and Chief Legal Officer
Forward Guidance
The company is preparing for phase III trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...